{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"13"}]}],"title":"Grade 3 Adverse Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"0"}]}],"title":"Grade 4 Adverse Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Grade 5 Adverse Event"}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"55"},{"groupId":"OG005","value":"24"}],"units":"Participants"}],"description":"Adverse events are defined as events that are classified as either possibly, probably, or definitely related to study treatment, graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0. The number of patients reporting grade 3 or higher adverse events at least possibly related to treatment are reported here. For a complete list of all reported adverse events, please see the adverse events section of this report.","groups":[{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Endometrial Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Ovarian Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Hepatocellular Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Carcinoid Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"Islet Cell (Double Agent) Cohort"},{"description":"Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG005","title":"Islet Cell (Bevacizumab-only) Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients that received protocol treatment and were evaluated for adverse events are reported in this analysis.","reportingStatus":"POSTED","timeFrame":"Every cycle of treatment, up to 3 years","title":"Incidence of Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}